Oxagen Ltd

Novartis AG ’s asthma hopes have been dented somewhat by a Phase III miss for its small molecule candidate QAW039 (fevipiprant). In a note buried in its third-quarter results announcement, the group r

UK-based Redx Pharma has promoted Dr Richard Armer to chief scientific officer and Phil Tottey to chief financial officer. Mr Armer, who has previously worked for pharmaceutical firms including Pfizer

Shionogi is pressing ahead with a planned early Phase II programme in the US for its novel anti-allergic candidate S-555739, based on recent positive results from a Japanese trial. The once-daily oral

The pharmaceutical division of Teijin has acquired rights in Japan to Pulmagen Therapeutics' lead CRTh2 antagonist ADC3680, which it will develop initially for bronchial asthma. The deal is the first